AVIR

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative antiviral therapies to combat critical viral infections. Leveraging its proprietary technology platform, Atea aims to address pressing public health challenges posed by emerging viral threats through a diverse and robust pipeline of treatments. The company is committed to scientific excellence and has positioned itself to potentially revolutionize the standard of care for patients facing severe viral infections, making it a compelling investment opportunity in the biopharmaceutical space.